Jiangsu Nanfang Medical Co., Ltd. (SHA:603880)
China · Delayed Price · Currency is CNY 9.87
+0.15 (1.54%)
Sep 14, 2026, 3:00 PM CST
Jiangsu Nanfang Medical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,853 | 1,801 | 1,257 | 1,489 | 1,813 | 2,094 | |
Market Cap Growth | 54.70% | 43.22% | -15.54% | -17.90% | -13.41% | -26.66% |
Enterprise Value | 3,232 | 2,219 | 1,692 | 1,917 | 2,122 | 2,243 |
Last Close Price | 9.87 | 6.23 | 4.35 | 5.09 | 6.20 | 7.16 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 5.05 | 3.00 | 2.09 | 2.48 | 3.33 | 3.97 |
PB Ratio | 17.45 | 9.94 | 4.42 | 3.14 | 2.92 | 3.29 |
P/TBV Ratio | 23.89 | 13.20 | 5.31 | 3.47 | 3.15 | 3.52 |
P/FCF Ratio | 202.75 | 100.48 | 24.71 | - | - | - |
P/OCF Ratio | 177.07 | 84.99 | 22.45 | 95.99 | 57.98 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.72 | 3.70 | 2.81 | 3.19 | 3.89 | 4.25 |
EV/EBITDA Ratio | - | - | - | - | 142.77 | 174.34 |
EV/FCF Ratio | 229.70 | 123.80 | 33.26 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 2.65 | 2.51 | 1.75 | 0.99 | 0.76 | 0.56 |
Debt / EBITDA Ratio | - | - | - | - | 31.04 | 27.15 |
Debt / FCF Ratio | 30.78 | 25.32 | 9.77 | - | - | - |
Net Debt / Equity Ratio | 2.29 | 2.24 | 1.49 | 0.74 | 0.52 | 0.28 |
Net Debt / EBITDA Ratio | -11.33 | -13.20 | -4.66 | -9.62 | 21.83 | 14.07 |
Net Debt / FCF Ratio | 26.66 | 22.63 | 8.34 | -6.93 | -2.82 | -0.61 |
Asset Turnover | 0.61 | 0.61 | 0.52 | 0.44 | 0.41 | 0.46 |
Inventory Turnover | 3.77 | 3.58 | 2.77 | 2.04 | 1.89 | 2.58 |
Quick Ratio | 0.25 | 0.27 | 0.27 | 0.36 | 0.46 | 0.56 |
Current Ratio | 0.45 | 0.49 | 0.54 | 0.72 | 0.84 | 1.00 |
Return on Equity (ROE) | -48.64% | -43.44% | -50.22% | -26.88% | -2.38% | -3.45% |
Return on Assets (ROA) | -5.50% | -5.09% | -7.55% | -4.15% | -1.22% | -0.87% |
Return on Invested Capital (ROIC) | -14.99% | -12.47% | -18.39% | -10.25% | -2.99% | -2.34% |
Return on Capital Employed (ROCE) | -35.30% | -30.50% | -44.60% | -18.70% | -4.10% | -2.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -3.73% | -5.65% | -15.17% | -9.90% | -0.81% | -1.09% |
FCF Yield | 0.49% | 1.00% | 4.05% | -3.40% | -6.33% | -14.13% |
Buyback Yield / Dilution | 3.25% | -0.59% | 0.06% | 1.34% | -2.97% | 0.60% |
Total Shareholder Return | 3.25% | -0.59% | 0.06% | 1.34% | -2.97% | 0.60% |